NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis $23.20 +1.09 (+4.93%) Closing price 03:59 PM EasternExtended Trading$23.17 -0.03 (-0.13%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alto Neuroscience Stock (NYSE:ANRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alto Neuroscience alerts:Sign Up Key Stats Today's Range$21.90▼$23.3550-Day Range$21.70▼$36.7552-Week Range$10.20▼$37.48Volume469,251 shsAverage Volume426,874 shsMarket Capitalization$910.38 millionP/E RatioN/ADividend YieldN/APrice Target$37.88Consensus RatingModerate Buy Company Overview Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and central nervous system disorders. The company combines neuroscience research, clinical data and biomarker-based approaches to identify patients who may be more likely to respond to specific treatments. Alto Neuroscience’s investigational pipeline includes therapies intended to address conditions such as major depressive disorder, bipolar depression, schizophrenia and associated cognitive impairment. Its programs are designed to target biological mechanisms underlying these disorders and may be evaluated alongside biomarkers or other patient characteristics to support more personalized treatment decisions. The company was founded by Amit Etkin, M.D., Ph.D., a neuroscientist and psychiatrist who serves as its chief executive officer. Alto Neuroscience is headquartered in the United States and conducts research and clinical development activities through collaborations and studies involving patients and research sites in relevant markets. Its product candidates remain investigational and have not been approved for commercial use.AI Generated. May Contain Errors. Read More Alto Neuroscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreANRO MarketRank™: 2.392258064515 of 5 starsAlto Neuroscience scored higher than 48% of companies evaluated by MarketBeat, and ranked 592nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAlto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAlto Neuroscience has a consensus price target of $37.88, representing about 63.3% upside from its current price of $23.20.Amount of Analyst CoverageAlto Neuroscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alto Neuroscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alto Neuroscience are expected to decrease in the coming year, from ($2.69) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alto Neuroscience is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alto Neuroscience is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlto Neuroscience has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alto Neuroscience's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.94% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Alto Neuroscience has recently increased by 11.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentAlto Neuroscience has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Alto Neuroscience this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,566,987.00 in company stock.Percentage Held by Insiders11.25% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAlto Neuroscience has minimal institutional ownership at this time.Read more about Alto Neuroscience's insider trading history. Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANRO Stock News HeadlinesANRO Stock Earnings Estimates Decreased by HC WainwrightOctober 23, 2026 | americanbankingnews.comAlto Neuroscience, Inc. (ANRO) - What Are Brokerages Saying About This Stock?October 22, 2026 | americanbankingnews.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 27 at 1:00 AM | Stansberry Research (Ad)Alto Neuroscience (NYSE:ANRO) Shares Gap Up on Analyst UpgradeOctober 22, 2026 | americanbankingnews.comAlto Neuroscience (NYSE:ANRO) Stock Gets Price Target Boost from HC WainwrightOctober 21, 2026 | americanbankingnews.comHC Wainwright Adjusts Alto Neuroscience Price Target to $60 From $55, Maintains Buy RatingOctober 19, 2026 | marketscreener.comMAlto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To HoldOctober 15, 2026 | seekingalpha.comInsider Selling: Alto Neuroscience (NYSE:ANRO) CFO Sells $621,125.92 in StockOctober 2, 2026 | insidertrades.comSee More Headlines ANRO Stock Analysis - Frequently Asked Questions How have ANRO shares performed this year? Alto Neuroscience's stock was trading at $17.82 at the start of the year. Since then, ANRO shares have increased by 30.2% and is now trading at $23.1990. How were Alto Neuroscience's earnings last quarter? Alto Neuroscience, Inc. (NYSE:ANRO) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.08. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $121 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at $14.00-$16.00 per share. Who are Alto Neuroscience's major shareholders? Alto Neuroscience's top institutional investors include Revisor Wealth Management LLC (0.03%), GK Wealth Management LLC (0.02%), Farther Finance Advisors LLC (0.01%) and Sterling Capital Management LLC. Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith. View institutional ownership trends. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alto Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include Advanced Micro Devices (AMD), Alphabet (GOOG), PayPal (PYPL), NVIDIA (NVDA), Airship AI (AISP), Dell Technologies (DELL) and Arcellx (ACLX). Company Calendar Last Earnings8/12/2026Today10/27/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ANRO's financial health is in the Green zone, according to TradeSmith. ANRO has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CIK1999480 Webwww.altoneuroscience.com Phone(773) 255-5012FaxN/AEmployees68Year Founded2019Price Target and Rating Average Price Target for Alto Neuroscience$37.88 High Price Target$60.00 Low Price Target$26.00 Potential Upside/Downside+63.3%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.46% Return on Assets-39.09% Debt Debt-to-Equity Ratio0.07 Current Ratio14.85 Quick Ratio14.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.87 per share Price / Book4.76Miscellaneous Outstanding Shares39,242,000Free Float34,827,000Market Cap$910.38 million OptionableOptionable Beta1.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:ANRO) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
